Tag Archives: Harald Hasselmann

Eckert & Ziegler Supports Development of DARPin Radiolabeled Cancer Therapies Using Actinium-225 and Lutetium-177

(IN BRIEF) Eckert & Ziegler SE and Molecular Partners AG have entered into a partnership to develop and potentially manufacture DARPin-based radiopharmaceutical therapies for cancer treatment. Eckert & Ziegler will provide development services for Radio-DARPins using Actinium-225 and Lutetium-177 isotopes, … Read the full press release

Eckert & Ziegler to Supply Clinical-Grade Y90-PentixaTher Doses for Pentixapharm Trials

(IN BRIEF) Eckert & Ziegler Radiopharma GmbH has entered into a clinical manufacturing agreement with Pentixapharm AG to supply GMP-grade Y90-PentixaTher doses for use in ongoing trials. The radiolabeled therapy targets cancers overexpressing the CXCR4 receptor and supports a theranostic … Read the full press release